SrasV1, PubMed, Curation, bibRecord, 001C39

Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection.

Identifieur interne : 001C39 ( PubMed/Curation ); précédent : 001C38; suivant : 001C40

Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection.

Auteurs : Lanying Du [République populaire de Chine] ; Guangyu Zhao ; Yongping Lin ; Hongyan Sui ; Chris Chan ; Selene Ma ; Yuxian He ; Shibo Jiang ; Changyou Wu ; Kwok-Yung Yuen ; Dong-Yan Jin ; Yusen Zhou ; Bo-Jian Zheng

Source :

Journal of immunology (Baltimore, Md. : 1950) [ 0022-1767 ] ; 2008.

RBID : pubmed:18178835

Descripteurs français

English descriptors

KwdEn :
- Administration, Intranasal, Animals, Antibody Formation, BALB 3T3 Cells, Dependovirus (genetics), Humans, Immunity, Mucosal, Immunoglobulin A (immunology), Lung (immunology), Membrane Glycoproteins (administration & dosage), Membrane Glycoproteins (genetics), Membrane Glycoproteins (immunology), Mice, SARS Virus (drug effects), SARS Virus (physiology), Severe Acute Respiratory Syndrome (prevention & control), Spike Glycoprotein, Coronavirus, Spleen (immunology), T-Lymphocytes, Cytotoxic (immunology), Vaccination, Viral Envelope Proteins (administration & dosage), Viral Envelope Proteins (genetics), Viral Envelope Proteins (immunology), Viral Vaccines (administration & dosage), Viral Vaccines (genetics), Viral Vaccines (immunology), Virus Replication (drug effects).
MESH :
- chemical , administration & dosage : Membrane Glycoproteins, Viral Envelope Proteins, Viral Vaccines.
- chemical , genetics : Membrane Glycoproteins, Viral Envelope Proteins, Viral Vaccines.
- chemical , immunology : Immunoglobulin A, Membrane Glycoproteins, Viral Envelope Proteins, Viral Vaccines.
- drug effects : SARS Virus, Virus Replication.
- genetics : Dependovirus.
- immunology : Lung, Spleen, T-Lymphocytes, Cytotoxic.
- physiology : SARS Virus.
- prevention & control : Severe Acute Respiratory Syndrome.
- Administration, Intranasal, Animals, Antibody Formation, BALB 3T3 Cells, Humans, Immunity, Mucosal, Mice, Spike Glycoprotein, Coronavirus, Vaccination.

Abstract

We have previously reported that a subunit protein vaccine based on the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein and a recombinant adeno-associated virus (rAAV)-based RBD (RBD-rAAV) vaccine could induce highly potent neutralizing Ab responses in immunized animals. In this study, systemic, mucosal, and cellular immune responses and long-term protective immunity induced by RBD-rAAV were further characterized in a BALB/c mouse model, with comparison of the i.m. and intranasal (i.n.) routes of administration. Our results demonstrated that: 1) the i.n. vaccination induced a systemic humoral immune response of comparable strength and shorter duration than the i.m. vaccination, but the local humoral immune response was much stronger; 2) the i.n. vaccination elicited stronger systemic and local specific cytotoxic T cell responses than the i.m. vaccination, as evidenced by higher prevalence of IL-2 and/or IFN-gamma-producing CD3+/CD8+ T cells in both lungs and spleen; 3) the i.n. vaccination induced similar protection as the i.m. vaccination against SARS-CoV challenge in mice; 4) higher titers of mucosal IgA and serum-neutralizing Ab were associated with lower viral load and less pulmonary pathological damage, while no Ab-mediated disease enhancement effect was observed; and 5) the vaccination could provide long-term protection against SARS-CoV infection. Taken together, our findings suggest that RBD-rAAV can be further developed into a vaccine candidate for prevention of SARS and that i.n. vaccination may be the preferred route of administration due to its ability to induce SARS-CoV-specific systemic and mucosal immune responses and its better safety profile.

DOI: 10.4049/jimmunol.180.2.948
PubMed: 18178835

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001C39

Links to Exploration step

pubmed:18178835

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection.</title>
<author><name sortKey="Du, Lanying" sort="Du, Lanying" uniqKey="Du L" first="Lanying" last="Du">Lanying Du</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology, University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Microbiology, University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Zhao, Guangyu" sort="Zhao, Guangyu" uniqKey="Zhao G" first="Guangyu" last="Zhao">Guangyu Zhao</name>
</author>
<author><name sortKey="Lin, Yongping" sort="Lin, Yongping" uniqKey="Lin Y" first="Yongping" last="Lin">Yongping Lin</name>
</author>
<author><name sortKey="Sui, Hongyan" sort="Sui, Hongyan" uniqKey="Sui H" first="Hongyan" last="Sui">Hongyan Sui</name>
</author>
<author><name sortKey="Chan, Chris" sort="Chan, Chris" uniqKey="Chan C" first="Chris" last="Chan">Chris Chan</name>
</author>
<author><name sortKey="Ma, Selene" sort="Ma, Selene" uniqKey="Ma S" first="Selene" last="Ma">Selene Ma</name>
</author>
<author><name sortKey="He, Yuxian" sort="He, Yuxian" uniqKey="He Y" first="Yuxian" last="He">Yuxian He</name>
</author>
<author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name>
</author>
<author><name sortKey="Wu, Changyou" sort="Wu, Changyou" uniqKey="Wu C" first="Changyou" last="Wu">Changyou Wu</name>
</author>
<author><name sortKey="Yuen, Kwok Yung" sort="Yuen, Kwok Yung" uniqKey="Yuen K" first="Kwok-Yung" last="Yuen">Kwok-Yung Yuen</name>
</author>
<author><name sortKey="Jin, Dong Yan" sort="Jin, Dong Yan" uniqKey="Jin D" first="Dong-Yan" last="Jin">Dong-Yan Jin</name>
</author>
<author><name sortKey="Zhou, Yusen" sort="Zhou, Yusen" uniqKey="Zhou Y" first="Yusen" last="Zhou">Yusen Zhou</name>
</author>
<author><name sortKey="Zheng, Bo Jian" sort="Zheng, Bo Jian" uniqKey="Zheng B" first="Bo-Jian" last="Zheng">Bo-Jian Zheng</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2008">2008</date>
<idno type="RBID">pubmed:18178835</idno>
<idno type="pmid">18178835</idno>
<idno type="doi">10.4049/jimmunol.180.2.948</idno>
<idno type="wicri:Area/PubMed/Corpus">001C39</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001C39</idno>
<idno type="wicri:Area/PubMed/Curation">001C39</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001C39</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection.</title>
<author><name sortKey="Du, Lanying" sort="Du, Lanying" uniqKey="Du L" first="Lanying" last="Du">Lanying Du</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology, University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Microbiology, University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Zhao, Guangyu" sort="Zhao, Guangyu" uniqKey="Zhao G" first="Guangyu" last="Zhao">Guangyu Zhao</name>
</author>
<author><name sortKey="Lin, Yongping" sort="Lin, Yongping" uniqKey="Lin Y" first="Yongping" last="Lin">Yongping Lin</name>
</author>
<author><name sortKey="Sui, Hongyan" sort="Sui, Hongyan" uniqKey="Sui H" first="Hongyan" last="Sui">Hongyan Sui</name>
</author>
<author><name sortKey="Chan, Chris" sort="Chan, Chris" uniqKey="Chan C" first="Chris" last="Chan">Chris Chan</name>
</author>
<author><name sortKey="Ma, Selene" sort="Ma, Selene" uniqKey="Ma S" first="Selene" last="Ma">Selene Ma</name>
</author>
<author><name sortKey="He, Yuxian" sort="He, Yuxian" uniqKey="He Y" first="Yuxian" last="He">Yuxian He</name>
</author>
<author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name>
</author>
<author><name sortKey="Wu, Changyou" sort="Wu, Changyou" uniqKey="Wu C" first="Changyou" last="Wu">Changyou Wu</name>
</author>
<author><name sortKey="Yuen, Kwok Yung" sort="Yuen, Kwok Yung" uniqKey="Yuen K" first="Kwok-Yung" last="Yuen">Kwok-Yung Yuen</name>
</author>
<author><name sortKey="Jin, Dong Yan" sort="Jin, Dong Yan" uniqKey="Jin D" first="Dong-Yan" last="Jin">Dong-Yan Jin</name>
</author>
<author><name sortKey="Zhou, Yusen" sort="Zhou, Yusen" uniqKey="Zhou Y" first="Yusen" last="Zhou">Yusen Zhou</name>
</author>
<author><name sortKey="Zheng, Bo Jian" sort="Zheng, Bo Jian" uniqKey="Zheng B" first="Bo-Jian" last="Zheng">Bo-Jian Zheng</name>
</author>
</analytic>
<series><title level="j">Journal of immunology (Baltimore, Md. : 1950)</title>
<idno type="ISSN">0022-1767</idno>
<imprint><date when="2008" type="published">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Intranasal</term>
<term>Animals</term>
<term>Antibody Formation</term>
<term>BALB 3T3 Cells</term>
<term>Dependovirus (genetics)</term>
<term>Humans</term>
<term>Immunity, Mucosal</term>
<term>Immunoglobulin A (immunology)</term>
<term>Lung (immunology)</term>
<term>Membrane Glycoproteins (administration & dosage)</term>
<term>Membrane Glycoproteins (genetics)</term>
<term>Membrane Glycoproteins (immunology)</term>
<term>Mice</term>
<term>SARS Virus (drug effects)</term>
<term>SARS Virus (physiology)</term>
<term>Severe Acute Respiratory Syndrome (prevention & control)</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Spleen (immunology)</term>
<term>T-Lymphocytes, Cytotoxic (immunology)</term>
<term>Vaccination</term>
<term>Viral Envelope Proteins (administration & dosage)</term>
<term>Viral Envelope Proteins (genetics)</term>
<term>Viral Envelope Proteins (immunology)</term>
<term>Viral Vaccines (administration & dosage)</term>
<term>Viral Vaccines (genetics)</term>
<term>Viral Vaccines (immunology)</term>
<term>Virus Replication (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie nasale</term>
<term>Animaux</term>
<term>Cellules BALB 3T3</term>
<term>Dependovirus (génétique)</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Glycoprotéines membranaires (administration et posologie)</term>
<term>Glycoprotéines membranaires (génétique)</term>
<term>Glycoprotéines membranaires (immunologie)</term>
<term>Humains</term>
<term>Immunité muqueuse</term>
<term>Immunoglobuline A (immunologie)</term>
<term>Lymphocytes T cytotoxiques (immunologie)</term>
<term>Poumon (immunologie)</term>
<term>Production d'anticorps</term>
<term>Protéines de l'enveloppe virale (administration et posologie)</term>
<term>Protéines de l'enveloppe virale (génétique)</term>
<term>Protéines de l'enveloppe virale (immunologie)</term>
<term>Rate (immunologie)</term>
<term>Réplication virale ()</term>
<term>Souris</term>
<term>Syndrome respiratoire aigu sévère ()</term>
<term>Vaccination</term>
<term>Vaccins antiviraux (administration et posologie)</term>
<term>Vaccins antiviraux (génétique)</term>
<term>Vaccins antiviraux (immunologie)</term>
<term>Virus du SRAS ()</term>
<term>Virus du SRAS (physiologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Membrane Glycoproteins</term>
<term>Viral Envelope Proteins</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Membrane Glycoproteins</term>
<term>Viral Envelope Proteins</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Immunoglobulin A</term>
<term>Membrane Glycoproteins</term>
<term>Viral Envelope Proteins</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Glycoprotéines membranaires</term>
<term>Protéines de l'enveloppe virale</term>
<term>Vaccins antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term>
<term>Virus Replication</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Dependovirus</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Dependovirus</term>
<term>Glycoprotéines membranaires</term>
<term>Protéines de l'enveloppe virale</term>
<term>Vaccins antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Glycoprotéines membranaires</term>
<term>Immunoglobuline A</term>
<term>Lymphocytes T cytotoxiques</term>
<term>Poumon</term>
<term>Protéines de l'enveloppe virale</term>
<term>Rate</term>
<term>Vaccins antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Lung</term>
<term>Spleen</term>
<term>T-Lymphocytes, Cytotoxic</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Administration, Intranasal</term>
<term>Animals</term>
<term>Antibody Formation</term>
<term>BALB 3T3 Cells</term>
<term>Humans</term>
<term>Immunity, Mucosal</term>
<term>Mice</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Vaccination</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Administration par voie nasale</term>
<term>Animaux</term>
<term>Cellules BALB 3T3</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Humains</term>
<term>Immunité muqueuse</term>
<term>Production d'anticorps</term>
<term>Réplication virale</term>
<term>Souris</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Vaccination</term>
<term>Virus du SRAS</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We have previously reported that a subunit protein vaccine based on the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein and a recombinant adeno-associated virus (rAAV)-based RBD (RBD-rAAV) vaccine could induce highly potent neutralizing Ab responses in immunized animals. In this study, systemic, mucosal, and cellular immune responses and long-term protective immunity induced by RBD-rAAV were further characterized in a BALB/c mouse model, with comparison of the i.m. and intranasal (i.n.) routes of administration. Our results demonstrated that: 1) the i.n. vaccination induced a systemic humoral immune response of comparable strength and shorter duration than the i.m. vaccination, but the local humoral immune response was much stronger; 2) the i.n. vaccination elicited stronger systemic and local specific cytotoxic T cell responses than the i.m. vaccination, as evidenced by higher prevalence of IL-2 and/or IFN-gamma-producing CD3+/CD8+ T cells in both lungs and spleen; 3) the i.n. vaccination induced similar protection as the i.m. vaccination against SARS-CoV challenge in mice; 4) higher titers of mucosal IgA and serum-neutralizing Ab were associated with lower viral load and less pulmonary pathological damage, while no Ab-mediated disease enhancement effect was observed; and 5) the vaccination could provide long-term protection against SARS-CoV infection. Taken together, our findings suggest that RBD-rAAV can be further developed into a vaccine candidate for prevention of SARS and that i.n. vaccination may be the preferred route of administration due to its ability to induce SARS-CoV-specific systemic and mucosal immune responses and its better safety profile.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18178835</PMID>
<DateCompleted><Year>2008</Year>
<Month>03</Month>
<Day>10</Day>
</DateCompleted>
<DateRevised><Year>2019</Year>
<Month>05</Month>
<Day>16</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-1767</ISSN>
<JournalIssue CitedMedium="Print"><Volume>180</Volume>
<Issue>2</Issue>
<PubDate><Year>2008</Year>
<Month>Jan</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
<ISOAbbreviation>J. Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection.</ArticleTitle>
<Pagination><MedlinePgn>948-56</MedlinePgn>
</Pagination>
<Abstract><AbstractText>We have previously reported that a subunit protein vaccine based on the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein and a recombinant adeno-associated virus (rAAV)-based RBD (RBD-rAAV) vaccine could induce highly potent neutralizing Ab responses in immunized animals. In this study, systemic, mucosal, and cellular immune responses and long-term protective immunity induced by RBD-rAAV were further characterized in a BALB/c mouse model, with comparison of the i.m. and intranasal (i.n.) routes of administration. Our results demonstrated that: 1) the i.n. vaccination induced a systemic humoral immune response of comparable strength and shorter duration than the i.m. vaccination, but the local humoral immune response was much stronger; 2) the i.n. vaccination elicited stronger systemic and local specific cytotoxic T cell responses than the i.m. vaccination, as evidenced by higher prevalence of IL-2 and/or IFN-gamma-producing CD3+/CD8+ T cells in both lungs and spleen; 3) the i.n. vaccination induced similar protection as the i.m. vaccination against SARS-CoV challenge in mice; 4) higher titers of mucosal IgA and serum-neutralizing Ab were associated with lower viral load and less pulmonary pathological damage, while no Ab-mediated disease enhancement effect was observed; and 5) the vaccination could provide long-term protection against SARS-CoV infection. Taken together, our findings suggest that RBD-rAAV can be further developed into a vaccine candidate for prevention of SARS and that i.n. vaccination may be the preferred route of administration due to its ability to induce SARS-CoV-specific systemic and mucosal immune responses and its better safety profile.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Du</LastName>
<ForeName>Lanying</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology, University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zhao</LastName>
<ForeName>Guangyu</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lin</LastName>
<ForeName>Yongping</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Sui</LastName>
<ForeName>Hongyan</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><LastName>Chan</LastName>
<ForeName>Chris</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ma</LastName>
<ForeName>Selene</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>He</LastName>
<ForeName>Yuxian</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Jiang</LastName>
<ForeName>Shibo</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Wu</LastName>
<ForeName>Changyou</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Yuen</LastName>
<ForeName>Kwok-Yung</ForeName>
<Initials>KY</Initials>
</Author>
<Author ValidYN="Y"><LastName>Jin</LastName>
<ForeName>Dong-Yan</ForeName>
<Initials>DY</Initials>
</Author>
<Author ValidYN="Y"><LastName>Zhou</LastName>
<ForeName>Yusen</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Zheng</LastName>
<ForeName>Bo-Jian</ForeName>
<Initials>BJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>R01 AI068002</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 AI068002-02</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 AI68002</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Immunol</MedlineTA>
<NlmUniqueID>2985117R</NlmUniqueID>
<ISSNLinking>0022-1767</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007070">Immunoglobulin A</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000281" MajorTopicYN="N">Administration, Intranasal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000917" MajorTopicYN="N">Antibody Formation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D041702" MajorTopicYN="N">BALB 3T3 Cells</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000229" MajorTopicYN="N">Dependovirus</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018928" MajorTopicYN="N">Immunity, Mucosal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007070" MajorTopicYN="N">Immunoglobulin A</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013154" MajorTopicYN="N">Spleen</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013602" MajorTopicYN="N">T-Lymphocytes, Cytotoxic</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year>
<Month>1</Month>
<Day>8</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2008</Year>
<Month>3</Month>
<Day>11</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2008</Year>
<Month>1</Month>
<Day>8</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">18178835</ArticleId>
<ArticleId IdType="pii">180/2/948</ArticleId>
<ArticleId IdType="pmc">PMC2603051</ArticleId>
<ArticleId IdType="mid">NIHMS81924</ArticleId>
<ArticleId IdType="doi">10.4049/jimmunol.180.2.948</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Virol. 2006 Sep;80(18):9279-87</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16940539</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2006 Sep 15;353(1):6-16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16793110</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Biophys Res Commun. 2007 Jul 20;359(1):174-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17533109</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2007 Sep 28;25(39-40):6981-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17709158</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2003 Oct 25;362(9393):1353-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14585636</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gene Med. 2003 Nov;5(11):941-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14601131</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2003 Dec 6;362(9399):1895-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14667748</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Ther. 2000 Dec;2(6):619-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11124063</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hum Gene Ther. 2001 Jun 10;12(9):1047-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11399227</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2001 Jul 20;19(30):4219-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11457548</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Viral Immunol. 2006 Summer;19(3):518-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16987069</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann N Y Acad Sci. 2006 Oct;1081:130-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17135502</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2007 Jan 2;25(1):136-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16919855</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Transl Oncol. 2006 Dec;8(12):858-67</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17169759</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>AIDS Res Hum Retroviruses. 2007 Jan;23(1):67-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17263635</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2007 Feb 26;25(10):1771-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17224217</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2007 Apr 12;25(15):2832-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17092615</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2001 Oct;75(19):9493-501</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11533211</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2002 Mar;76(6):2667-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11861833</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Gene Ther. 2002 May;2(2):145-59</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12109212</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2002 Sep 1;100(5):1655-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12176885</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hum Gene Ther. 2002 Sep 1;13(13):1571-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12228012</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2003 Feb;77(3):1904-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12525625</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Immunol. 2002 Nov;32(11):3294-304</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12555675</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 May 15;348(20):1948-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12748314</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2003 Aug;77(16):8801-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12885899</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2003 Oct 10;302(5643):276-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12958366</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Gene Ther. 2003 Dec;3(6):545-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14683451</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Acta Biochim Biophys Sin (Shanghai). 2004 Jan;36(1):37-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14732873</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2004 Feb 13;303(5660):944-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14963300</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2004 Apr 1;428(6982):561-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15024391</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6641-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15096611</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2004 Jun 26;363(9427):2122-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15220033</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9804-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15210961</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>DNA Cell Biol. 2004 Jun;23(6):391-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15231072</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antivir Ther. 2004 Jun;9(3):365-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15259899</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Ther. 2004 Oct;10(4):671-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15451451</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Biophys Res Commun. 2004 Nov 12;324(2):773-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15474494</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Alzheimers Dis. 2004 Oct;6(5):483-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15505369</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2004 Nov;78(22):12672-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15507655</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1999 Oct;73(10):8549-58</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10482608</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1999 Nov;73(11):9485-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10516057</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2005 Jan 4;23(7):924-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15603894</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2005 Mar;79(5):2678-88</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15708987</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2005 Mar 18;23(17-18):2273-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15755610</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2005 Apr 8;23(20):2614-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15780444</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2005 Apr 10;334(2):160-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15780866</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2005 Apr 15;174(8):4908-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15814718</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 2005 May;86(Pt 5):1435-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15831955</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Gene Ther. 2005 Jun;5(3):323-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15975009</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virus Res. 2005 Sep;112(1-2):24-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16022898</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2005 Sep 30;340(2):174-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16043204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14040-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16169905</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2005 Oct 28;310(5748):676-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16195424</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2006 Jan 30;24(5):652-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16214268</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Immunol. 2005 Oct;237(2):96-105</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16337931</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2006 Mar;80(6):2621-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16501072</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2006 Apr 24;24(17):3624-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16497416</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2006 Apr;80(8):4079-87</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16571824</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Toxicol Sci. 2006 Jun;91(2):620-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16569728</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hum Gene Ther. 2006 May;17(5):500-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16716107</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Microbiol. 2006 Jul;55(Pt 7):923-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16772421</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Intervirology. 2006;49(5):307-18</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16809936</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C39 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001C39 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:18178835
   |texte=   Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:18178835" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection.

Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki